AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Tubulinyl-Tyr carboxypeptidase 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q7L8A9

UPID:

VASH1_HUMAN

Alternative names:

Tubulin carboxypeptidase 1; Tyrosine carboxypeptidase 1; Vasohibin-1

Alternative UPACC:

Q7L8A9; Q96H02; Q9UBF4; Q9Y629

Background:

Tubulinyl-Tyr carboxypeptidase 1, also known as Vasohibin-1, plays a pivotal role in microtubule dynamics by removing the C-terminal tyrosine residue of alpha-tubulin. This action is crucial for spindle function and accurate chromosome segregation during mitosis, highlighting its importance in cell division and genetic stability.

Therapeutic significance:

Understanding the role of Tubulinyl-Tyr carboxypeptidase 1 could open doors to potential therapeutic strategies. Its unique function in regulating mitotic spindle length and positioning, coupled with its selective inhibition of endothelial cell migration and angiogenesis, positions it as a target of interest in cancer research and treatment of angiogenesis-related diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.